Overview

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Tobira Therapeutics, Inc.
Collaborator:
ViiV Healthcare
Treatments:
Cenicriviroc
Dolutegravir
Midazolam
TAK-652